干擾素BETA藥物市場：依產品類型、給藥途徑、配銷通路及地區

2023年乾擾素BETA產品的全球市場規模預估為42.2億美元，預測期內（2023-2030年）年複合成長率為4.0%。

干擾素BETA產品的全球市場佔有率（%），依產品類型，2023年

干擾素BETA用於治療復發型多發性硬化症 (MS)，包括臨床孤立症候群、復發緩解型疾病和活動性進行性疾病。儘管這種藥物不能完全治癒這種疾病，但它可以減緩某些殘疾症狀的進展並減少復發次數。干擾素是人體內產生的天然物質，可以對抗感染疾病。干擾素BETA製劑分為乾擾素BETA-1A、干擾素BETA-1B、聚乙二醇化干擾素BETA-1A。

市場動態

多發性硬化症是一種神經系統疾病，會導致廣泛的殘疾，最常發生在 20 歲至 50 歲之間。根據多發性硬化症基金會（一個擁有 501 名成員的多發性硬化症患者及其家人的非營利組織）的數據，2020 年 1 月，這種自體自體免疫疾病影響了 250 萬人，全球年度發生率約為每10 萬人中7 例。患病範圍為每 10 萬人 50 至 120 人，取決於種族和地理緯度。此外，根據多發性硬化症基金會2021年發布的資料，美國估計有40萬人患有此病，每週診斷出約200例新病例。根據總公司美國加州的健康資訊提供者 Healthline Media 2022 年 3 月的研究，多發性硬化症是繼充血性心臟衰竭之後的第二大常見疾病，每位患者年度的直接和間接醫療費用最高，從8,528 美元起至 54,244 美元。因此，多發性硬化症患病的增加是推動全球干擾素BETA製劑市場成長的主要要素。

本研究的主要特點

• 本報告對全球干擾素BETA藥物市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率。
• 它還揭示了各個細分市場的潛在收入機會，並為該市場說明了一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
• 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球干擾素 Beta 製藥市場的主要企業。
• 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
• 全球干擾素BETA製劑市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 相關人員可以透過用於分析全球干擾素BETA藥物市場的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的和假設

• 這項研究的目的
• 假設
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 市場機會
• 影響分析
• 近期產品發布
• 流行病學
• 合併、收購和合作
• 法規場景
• 主要進展
• PEST分析

第4章 全球干擾素BETA製劑市場，COVID-19的影響分析

• 經濟影響
• 新型冠狀病毒（COVID-19）的流行病學
• 對需求和供給的影響

第5章 全球干擾素BETA藥物市場，依產品類型，2018-2030

• 干擾素BETA-1A
• 干擾素BETA-1B
• 聚乙二醇干擾素BETA-1A

第6章 全球干擾素BETA藥物市場，依給藥途徑，2018-2030

• 肌肉注射
• 皮下的
• 靜脈

第7章 全球干擾素BETA藥物市場，依配銷通路，2018-2030

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 2018-2030年全球干擾素BETA製劑市場（按地區）

• 北美洲
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• ASEAN
• 澳洲
• 韓國
• 其他亞太地區
• 中東
• GCC
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中部非洲
• 南非

第9章 競爭形勢

• Biogen
• Merck KGaA
• Novartis AG
• Bayer AG

第10章 章

• 調查方法
• 關於出版商

The global interferon beta drugs market is estimated to be valued at US$ 4.22 Bn in 2023 and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Global Interferon Beta Drugs Market Share (%), by Product Type, 2023

Interferon beta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but it slows down the progression of some of the disabling effects and decreases the number of relapses. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized as Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group of 20-50 years. According to the Multiple Sclerosis Foundation, a 501 non-profit organization benefiting people with multiple sclerosis and their families, in January 2020, this autoimmune condition affected 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the data published by the Multiple Sclerosis Foundation in 2021, an estimated 400,000 people live with the disease in the U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, a provider of health information headquartered in California, U.S., in March 2022, multiple sclerosis ranks second after congestive heart failure, with direct and indirect health care costs ranging from US$8,528 to US$54,244 per patient per year. Thus, the increasing prevalence of multiple sclerosis is a major factor driving the growth of the global interferon beta drugs market.

Key features of the study:

• This report provides an in-depth analysis of the global interferon beta drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global interferon beta drugs market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, Merck KGaA, Novartis AG and Bayer AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

• Global Interferon Beta Drugs Market, By Product Type:
  • Interferon Beta-1A
  • Interferon Beta-1B
  • Peginterferon Beta-1A
• Global Interferon Beta Drugs Market, By Route of Administration:
  • Intramuscular
  • Subcutaneous
  • Intravenous
• Global Interferon Beta Drugs Market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Interferon Beta Drugs Market, By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America

Middle East & Africa

• Company Profiles
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Bayer AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Route Of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Interferon Beta Drugs Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Interferon Beta Drugs Market, By Product Type, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Interferon Beta-1A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Interferon Beta-1B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Peginterferon Beta-1A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Interferon Beta Drugs Market, By Route Of Administration, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Interferon Beta Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Interferon Beta Drugs Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2018-2030, (US$ Bn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us